Status:
COMPLETED
Study of Methyl Aminolaevulinate Photodynamic Therapy With and Without Er:YAG Laser in Bowen's Disease
Lead Sponsor:
Dong-A University
Conditions:
Bowen's Disease
Eligibility:
All Genders
18-92 years
Phase:
PHASE1
Brief Summary
Methyl aminolaevulinate photodynamic therapy (MAL-PDT) is an effective treatment for Bowen's disease (BD) of the lower extremities. Er:YAG ablative fractional laser (AFL) treatment removes the stratum...
Detailed Description
Bowen's disease (BD) is a form of intraepidermal (in situ) squamous cell carcinoma (SCC) originally described in 1912.1 It presents as a gradually enlarging, well-demarcated erythematous plaque with a...
Eligibility Criteria
Inclusion
- Korean patients aged ≥ 18 years who had biopsy-confirmed BD lesions on the lower extremities
Exclusion
- porphyria,
- known allergies to the MAL cream or lidocaine,
- pregnancy,
- lactation,
- any active systemic infectious disease,
- immunosuppressive treatment,
- personal history of malignant melanoma,
- tendency towards melasma or keloid formation,
- prior treatment of the lesions within 4 weeks, and
- any indication of poor compliance
Key Trial Info
Start Date :
March 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01912976
Start Date
March 1 2011
End Date
March 1 2012
Last Update
August 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Dong-A University
Busan, Dong Dae Sin-dong, Seo-gu, South Korea, 602-715